Mr. Ashish Malik reports

BEE VECTORING TECHNOLOGIES ANNOUNCES A SECOND YEAR OF SUCCESSFUL SEED TREATMENT TRIAL RESULTS

Bee Vectoring Technologies International Inc. (BVT) has released positive second-year trial results demonstrating the efficacy of Bee Vectoring Technologies International's proprietary biological control agent Clonostachys rosea strain CR-7 (CR-7) as a seed treatment on soybeans.

Compared with the first-year trials, the second-year included measuring CR-7's effect on soybean yields. Year 2 trial data established that: adding CR-7 over base seed treatment results in soybean plants producing higher yields as measured over 16 replicated plots across four locations when compared with the biological standard; and that CR-7 was equivalent to the chemical standard in terms of effectiveness. Other measures on plant health, vigor and plant biomass showed the same positive outcomes as in the first year, indicating the scalability of Bee Vectoring Technologies International's proprietary CR-7 in the soybean seed treatment market.

"Wherever CR-7 was applied, the results outperformed the base seed treatment 81 per cent of the time. We observed, on average, a three-bushel yield per acre increase with CR-7 added, which is about 4 per cent higher than the base seed treatment. Although that may not sound dramatic, that is a meaningful improvement for a treatment that was applied at the very early stages of the planting season. Most seed treatments are designed to protect the seed from pests, but to see a positive increase in the yield at the end of the season is impressive," said Dr. Mason Newark, field technical manager at Bee Vectoring Technologies International.

Year 1 and 2 trials were conducted in partnership with well-established soybean researchers in Iowa, Ill., and Wisconsin, with a fourth location in Nebraska added in 2022; they have resulted in consistently positive results year-over-year across all the states that have had trials so far. The 2022 trials continued assessing the efficacy of CR-7 added over base seed treatment on plant biomass and vigour, and demonstrated its effectiveness as a treatment against disease and soybean crop yields.

"Our corporate market strategy is to initially focus on soybeans as it's a major row crop where major multinationals are heavily invested in," said Ashish Malik, chief executive officer of Bee Vectoring Technologies International. There are 320 million acres grown globally, with 86 million acres in the United States, 98 million in Brazil and 40 million in Argentina. 80 per cent of American soybeans receive seed treatment before planting and approximately 50 per cent undergo a biological inoculant treatment.

The seed treatment market is specialized, with different and distinct channels in the major growing regions. A deep understanding of the genetics of seed varieties and access to the distinct channels, including relationships with seed companies, are important to successfully penetrate the market. Bee Vectoring Technologies International intends to partner with seed treatment companies which have the expertise and channel access to accelerate the company's reach into this soybean acreage. Bee Vectoring Technologies International believes future licensing agreements hold potential for significant annual royalties from this application.

"Partners, growers and seed companies all rely on multiyear data to ensure effectiveness, BVT's repeated positive results can therefore increase their confidence even more," continued Mr. Malik. "For partners, the strong trial data from years 1 and 2 demonstrates the value and potential of adding CR-7 to their portfolios and shows that CR-7 can create a differentiated product offering to the marketplace."

Second year trial results also confirmed that adding CR-7 over base seed treatment led to plants being healthier in the vegetative stage -- when leaves, stems and roots are growing to support the flowering and reproductive stages.

Year 2 data also reconfirmed CR-7's effectiveness against sudden death syndrome (SDS), a significant problem caused by Fusarium virguliforme, a soil-borne pathogen that attacks soybean roots and lower stems, affecting flowers and young pods and resulting in significant yield loss.

"CR-7 was statistically equivalent to both biological and chemical standard treatments for SDS," said Dr. Newark. "This disease data, coupled with CR-7's ability to grow healthier plants and improve yield, enables us to provide growers with a product that addresses many needs with zero negative effect on crop safety -- and help them implement more sustainable agricultural practices."

About Bee Vectoring Technologies International Inc.

Bee Vectoring Technologies International, an agriculture technology company, is a market disrupter with a significant global market opportunity in the $240-billion crop protection and fertilizer market. Bee Vectoring Technologies International has pioneered a natural precision agriculture system that replaces chemical pesticides and wasteful plant protection product spray applications by delivering biological pesticide alternatives to crops using commercially grown bees. Bee Vectoring Technologies International's award-winning technology, precision vectoring, is completely harmless to bees and allows minute amounts of naturally derived pesticides (called biologicals) to be delivered directly to blooms, providing improved crop protection and yield results than traditional chemical pesticides -- and improving the health of the soil, the microbiome and the environment. Currently, Bee Vectoring Technologies International has over 65 granted patents, over 35 patents pending in all major agricultural countries worldwide and U.S. EPA (Environmental Protection Agency) registration of its Vectorite with CR-7 (EPA Registration No. 90641-2) for sale as a registered biological fungicide for use on the labelled crops.

We seek Safe Harbor.